Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (CSTL) announced findings from a study in collaboration with the Melanoma Research Foundation, revealing that 90% of uveal melanoma (UM) patients value prognostic testing at diagnosis. The DecisionDx-UM test reportedly provides insights into personalized treatment options, significantly reduces decision regret, and is now the standard of care in many US oncology practices. Despite various risk classifications, most patients indicated comparable decision regret levels. The study underscores the importance of personalized information for patient care.
Castle Biosciences, Inc. (NASDAQ: CSTL) announced new data at the ASDP 59th Annual Meeting indicating that the DecisionDx-SCC test can provide significant risk stratification for patients with cutaneous squamous cell carcinoma (cSCC) and uncertain tumor differentiation. This study, which involved 420 patients, revealed that 40% had changing BWH staging based on differentiation status alterations. Furthermore, low-risk patients demonstrated a three-year metastasis-free survival rate of 90.1%, outperforming moderate and high-risk groups, underscoring the test's value in guiding treatment decisions.
Summary not available.
Castle Biosciences, Inc. (CSTL) reported a 58% revenue increase to $37.0 million in Q3 2022, delivering a record 12,114 test reports, a 57% rise from Q3 2021. Adjusted revenues reached $37.3 million, marking a similar 58% growth. The company raised its 2022 revenue guidance to $132-137 million from $130-135 million. Despite the strong top-line growth, Castle Biosciences experienced a net loss of $(20.2) million for the quarter, worsening from $(11.8) million in Q3 2021. Gross margins were reported at 70%, with expectations for positive net operating cash flow by 2025.
Castle Biosciences, Inc. (NASDAQ: CSTL) will present company overviews at multiple investor conferences this November. These include the Credit Suisse 31st Annual Healthcare Conference on Nov. 9, 2022, at 12:50 p.m. ET, the Stephens Annual Investment Conference on Nov. 16, 2022, at 11:00 a.m. ET, and the Canaccord Genuity MedTech Conference on Nov. 17, 2022, at 11:30 a.m. ET. Live webcasts will be accessible on their website, with replays available post-event.
Castle focuses on diagnostics, offering tests for skin cancers and other diseases.
Castle Biosciences (CSTL) announced the publication of clinical utility data in Cancer Investigation, revealing that clinicians are effectively using the DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma (SCC) patients. In the study, 98.1% of 2,503 samples were tested, with 68.8% classified as low-risk. The study reinforces the importance of risk assessment beyond traditional methods, as 75% of samples had multiple high-risk factors. Results indicate that the test aids in aligning treatment plans with patients' metastatic risks, potentially reducing overtreatment.
Castle Biosciences (CSTL) announced new data demonstrating the effectiveness of DecisionDx-Melanoma and DecisionDx-UM in accurately predicting the risk of death associated with melanoma in real-world patients. In collaboration with the National Cancer Institute, the studies showed that these tests can help identify low-risk patients who may avoid unnecessary therapies. The findings highlight potential healthcare cost reductions and improved treatment decisions, as evidenced by significant survival rate differences based on test results.
Castle Biosciences, Inc. (NASDAQ: CSTL) announced at the 2022 ACG Annual Scientific Meeting that its TissueCypher® Barrett's Esophagus Test significantly enhances management decisions for patients with low-grade dysplasia (LGD). The study showed that utilizing TissueCypher results led to a 58.4% likelihood of patients receiving appropriate management compared to 9.1% with standard care. This test aims to standardize care, reduce unnecessary therapies, and potentially lower esophageal cancer risks. The findings suggest a substantial impact on patient outcomes.
Castle Biosciences (NASDAQ: CSTL) announced positive results from its UTILISE study on DecisionDx-SCC, a test for managing cutaneous squamous cell carcinoma (cSCC). The data, shared at the 2022 Fall Clinical Dermatology Conference, indicates that over 80% of patients experienced favorable changes in management based on test results. Specifically, 42% of clinicians noted the test was the most influential factor in patient management, with 59% expressing increased confidence in treatment plans. This study aligns with prior findings on the test's clinical utility and risk stratification effectiveness.
Castle Biosciences, Inc. (NASDAQ: CSTL) announced significant findings from its DECIDE study at the 19th International Congress of the Society for Melanoma Research. The study reveals that DecisionDx-Melanoma test results influenced 85% of clinicians' decisions regarding sentinel lymph node biopsy (SLNB) procedures. Notably, the test associated with a 29% reduction in SLNBs for low-risk patients. The data emphasizes the test's role in guiding risk-aligned patient care, allowing patients with low biological risk to safely forgo SLNB, potentially avoiding unnecessary complications.